Resiquimod

Biological Activity

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.
   Martins K, Steffens J, van Tongeren S, Wells J, Bergeron A, Dickson S, Dye J, Salazar A, Bavari S
   PLoS ONE, 2014;9(2):e89735.
2. Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity.
   Derouazi M, Di Berardino-Besson W, Belnoue E, Hoepner S, Walther R, Benkhoucha M, Teta P, Dufour Y, Yacoub Maroun C, Salazar A, Martinvalet D, Dietrich P, Walker P
   Cancer Res, 2015;75(15):3020-31.
3. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.
   Lee et al.
   Arch.Pharm.Res., 2014;37:1234
4. Imiquimod and resiquimod as novel immunomodulators.
   Dockrell and Kinghorn
   J.Antimicrob.Chemother., 2001;48:751
5. R848, a toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclasts.
   Miyamoto et al.
   Cytotechnology., 2012;64:331
6. Modulation of TH1 and Th2 cytokine production with the immune response modifiers, R-848 and imiq.
   Wagner et al.
   Cell Immunol., 1999;191:10

Product Datasheets